Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
about
Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgeryMacular grid laser photocoagulation for branch retinal vein occlusionAnti-vascular endothelial growth factor for diabetic macular oedemaAnti-vascular endothelial growth factor for control of wound healing in glaucoma surgeryAnti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusionAntiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedemaAnti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusionRole of aflibercept for macular edema following branch retinal vein occlusion: comparison of clinical trialsClinical Trials in Branch Retinal Vein OcclusionThe role of aflibercept in the management of diabetic macular edemaCurrent perspectives on ranibizumabAn Endovascular Cannulation Needle with an Internal Wire for the Fragmentation of Thrombi in Retinal Vein OcclusionEFFICACY AND SAFETY OF INTRAVITREAL CONBERCEPT INJECTIONS IN MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION.Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study.Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials.Evaluation of hyperreflective foci as a prognostic factor of visual outcome in retinal vein occlusion.Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion.Role of inflammation in previously untreated macular edema with branch retinal vein occlusionPatient's self-recognition of reduced visual acuity due to recurrence of macular edema and prompt visitation to the hospital in retinal vein occlusion.Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative studyAn introduction to patient-reported outcome measures in ophthalmic research.Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update.Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion: a prospective observational study.Changes in Retinal Nonperfusion Associated with Suppression of Vascular Endothelial Growth Factor in Retinal Vein Occlusion.Ranibizumab for the treatment of degenerative ocular conditions.Economic considerations of macular edema therapiesThe burden of disease of retinal vein occlusion: review of the literature.Treatment of macular edema due to retinal vein occlusions.Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion.Anti-VEGF Agents for Ocular Angiogenesis and Vascular PermeabilityThe expanding role of vascular endothelial growth factor inhibitors in ophthalmology.Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.Evaluation of masking study participants to intravitreal injections in a randomized clinical trialHigh intravitreal TGF-β1 and MMP-9 levels in eyes with retinal vein occlusionSubthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting.Antiangiogenic therapy for ischemic retinopathies.Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculatureA safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitionersShort-duration focal pattern grid photocoagulation for macular edema secondary to branch retinal vein occlusion.
P2860
Q24186464-D6385ECD-D7B8-4A09-969D-073D29A107CFQ24187991-BFCD2ABD-5C54-427F-8F0B-0DABB429FCC1Q24193083-BBAE512D-CF12-40BF-BB94-8F44A8B2A329Q24200772-01CEBFCB-D0C7-4D9F-B219-19CB3A9634F6Q24201821-E389A68F-DFCF-4558-9A81-FA1AC2C377BBQ24202071-545647F3-62D3-4934-B9A1-9442EEEED73FQ24234750-D34DF20D-C104-49E4-AE93-1892671D33BAQ26750459-0436BBEB-C843-4CEA-817A-DE183AAC932DQ26767092-F6FADEE8-F5B8-4BC3-9687-D468EBF3A547Q26798348-623451CC-21A6-4C01-818A-D4600ED6F84CQ28082383-39E18AAD-A11B-4CB6-8556-84DDF3A78FA0Q30372587-9FB68760-B7F9-44A0-99B8-B4C7082E4855Q30490419-4A0E09A2-A09B-47AE-BA12-D648DB27F844Q31131691-6D059D32-1F4C-42F5-BDE1-CB91CDF6E7D4Q31155420-8998F2FB-9743-423A-A0FF-FB0A81273D64Q33607767-335052F0-7B82-4E93-906D-1A325D313AAFQ33648485-DE54EF91-6A02-4419-984A-9B7360741D53Q33656127-37179910-1636-42A6-9479-88F207AFD153Q33686686-8614423E-ACDB-40C4-876D-2DE059DB8E77Q33701661-5DC09864-94F2-4B5D-87A3-D3278014E369Q33759121-E5FEDC56-8240-458C-AF76-B5433A8A8862Q33770558-F1BCB40B-3A3E-4592-86CB-B130E2AE419BQ33795991-C5170E7B-5D5C-4261-888E-EBE93B30603CQ33828254-5F00674B-86EF-4692-809B-6BCF19FD1D95Q33831237-C4E2CEAC-2B2F-4E18-9C45-AA0DDFAA3785Q33878122-C60C8F97-C36A-4E40-9CF3-5CFC5FF23806Q33890866-ECC63C5F-96B8-49EF-AA47-0A65B4A129BCQ33918085-EF856706-E737-4C29-9544-3ECB900FB0CCQ33993712-ED6BF422-5351-4C4D-9328-C975E35DA17CQ34088274-94509A4D-72CD-4FF7-B03C-088C530FEFD5Q34115840-09834D4E-E1D2-4C32-BDFA-A97FE4A8F635Q34139793-413C8DB0-B605-4190-94FF-D0C08F917A2EQ34158304-E6520A11-684C-4F24-BF9A-195493B90461Q34200359-0D1A751F-DA9D-443F-BC12-E6A4954B9184Q34206455-EB1F3066-4432-4F88-B513-69E032B39318Q34293412-271DD8C8-5F95-475D-B7AA-2723617A2FA7Q34295974-C5C4F9D1-BE60-4850-A22B-943A2EAC1DB3Q34311551-DFFCA741-B4EB-4C91-BD11-DF17C633291FQ34325559-F976C5BB-D0A0-48AB-B50C-4F01AEF8FB6BQ34333307-E42BE122-67E2-453F-BCCE-B43F88A6298E
P2860
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Ranibizumab for macular edema ...... results of a phase III study.
@ast
Ranibizumab for macular edema ...... results of a phase III study.
@en
Ranibizumab for macular edema ...... results of a phase III study.
@nl
type
label
Ranibizumab for macular edema ...... results of a phase III study.
@ast
Ranibizumab for macular edema ...... results of a phase III study.
@en
Ranibizumab for macular edema ...... results of a phase III study.
@nl
prefLabel
Ranibizumab for macular edema ...... results of a phase III study.
@ast
Ranibizumab for macular edema ...... results of a phase III study.
@en
Ranibizumab for macular edema ...... results of a phase III study.
@nl
P2093
P1433
P1476
Ranibizumab for macular edema ...... results of a phase III study.
@en
P2093
Amy Chen Rundle
BRAVO Investigators
Jeffrey S Heier
Leonard Feiner
Namrata Saroj
Peter A Campochiaro
Roman G Rubio
Sarah Gray
Wendy Yee Murahashi
P304
1102-1112.e1
P356
10.1016/J.OPHTHA.2010.02.021
P577
2010-04-15T00:00:00Z